3 Results for "

innate immune cell infiltration

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "innate immune cell infiltration" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-146244
CAS No.: 525625-52-9
Purity:  98.32%
Synonyms: ODN 2006; PF-3512676; CpG 7909; ODN 7909
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .
loading...
    loading...
Cat. No.: HY-177338
CAS No.: 2361424-97-5
STING agonist-45 is a selective STING agonist (EC50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 + T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases .
loading...
    loading...
Cat. No.: HY-P99012
CAS No.: 1236278-28-6
Synonyms: ALD-518; BMS-945429
Clazakizumab (ALD-518; BMS-945429) is a monoclonal antibody inhibitor targeting IL-6 that binds to and blocks IL-6-mediated signaling (including trans-signaling), reducing STAT3 phosphorylation, innate immune cell infiltration, endothelial activation, and complement activation, thereby protecting the kidney from ischemia-reperfusion injury. Clazakizumab can be used in research on renal ischemia-reperfusion injury and obesity-related hypercoagulability .
loading...
    loading...